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OBJECTIVES: In real practice, patients are treated along the entire year so that
budget simulations should be adjusted to chronological patterns of oncological
assistance. Deferred budget impact analysis is undergone in order to assess long-
run economic implications of clinical decisions on first-line mCRC therapies in
Spain. METHODS: As metastatic colorectal cancer diagnosis is not affected by sea-
sonal influences, we have created a mathematical model assuming that a single
patient is diagnosed every month and this patient has a 53% possibility to harbor a
native K-Ras sequence. Calculi were arranged based on median duration of ther-
apy. For bevacizumab-based therapy, budget impact for year t1 begins at month
5 and beyond. For patients that receive cetuximab-based therapy, budget impact
for year t1 begins at month 7. The same approach was performed for doublets
without any monoclonal antibody. Prices for all drugs in Spain were assumed to
represent the best-value for each drug including all possibilities to reduce phar-
macy costs. For first line, median duration of therapy reported by randomized trials
was used to calculate the final budget. 70kg and 1.7 m were used as reference for
patient dose calculations. RESULTS: When K-Ras status is not tested and bevaci-
zumab-based schedules are administered to every patient, annual growth of bud-
get increases by 55-60%. If K-Ras status is analyzed and wild-type patients are
treated with cetuximab combinations and mutated patients receive bevacizumab,
yearly budget growth amounts to 39-41%. Annual budget growth is minimized
(25%) when K-Ras wt patients are treated with cetuximab combinations whereas
K-Ras mutated tumours received chemotherapy alone. CONCLUSIONS: Duration
of therapy plays a key role on budget impact estimations from both overall and year
to year perspectives. K-Ras based clinical decisions not only optimize outcomes as
measured by response rates but also minimize economic implications on annual
budget growths.
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OBJECTIVES: Immunonutrition (IN) with arginine has been demonstrated in many
randomized clinical trials (RCTs) to decrease the risk of complications and the
length of hospital stay (LOS) in cancer patients undergoing gastrointestinal (GI)
surgery (Cerantola et al. 2011). This study aims at assessing the cost-effectiveness
of IN for upper GI cancer patients undergoing surgery in the National Health Sys-
tem (NHS). METHODS: Clinical data were retrieved from the meta-analysis of Cer-
antola. Both the decrease in LOS due to IN and the relative risk (RR) of overall
complications (Chevrou-Severac et al, 2011) were taken into account. Hospital cost
data (upper GI cancer surgical patients) were extracted from the Healthcare Re-
source Group codes of the NHS Payment by Results 2011/12 and Hospital Episode
Statistics. The cost of stay based on the LOS for the IN and the control group were
calculated. Finally a sensitivity analysis of the baseline (control group) complica-
tion rate was carried out. RESULTS: The RR of overall complications were 0.69 for
pre-operative and 0.62 for peri-operative use of IN. The hopspital LOS decreased by
2.42 days ifor pre- and 1.63 days for peri-operative use of IN. Weighted national
average hospital cost (GI cancer surgey) was £829 per day. Weighted national av-
erage cost of stay for patients with complications was £9,766 per patient and £5,421
per patient without complications. Based on the LOS decrease, IN is cost-savings in
upper GI surgery compared to control (savingsf £1,955 to £1,093 per patient). Even
for an initial complication rate as low as 5% in the control group, pre-operative use
of IN led to savings. CONCLUSIONS: Immunonutrition is an effective and cost-
saving intervention for the NHS: savings up to £1,955 per patient-stay with pre-
operative use of IN. Immunonutrition in patients undergoing surgery for upper GI
cancer is an efficient intervention for British hospitals, as it decreases LOS, post-
surgical complications and hospital costs.
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OBJECTIVES: Image-Guided Radiation Therapy (IGRT) is an innovative technique
allowing three-dimensional control of the position of the anatomical target vol-
umes before or during sessions of irradiation. In case of prostate cancer, IGRT
allows clinicians to localize the tumor, either with Cone Beam Computed Tomog-
raphy (CBCT) or by portal imaging with Fiducial Markers (FM). A weekly positioning
control is generally carried out. However, daily controls has been recommended in
case of Intensity-Modulated Radiation Therapy (IMRT) delivering high dose in the
prostate. Therefore, a cost analysis investigating IGRT with CBCT and FM according
to the positioning frequency daily versus weekly in prostate cancers was
conducted. METHODS: The cost-analysis was performed in a multicenter random-
ized phase III trial. Patients included received radiotherapy for a localized prostate
adenocarcinoma. Cost calculations were strictly based on a micro costing approach
according to the hospitals’ point of view. Time horizon included radiation therapy.
All costs were given in 2009 euros. Comparisons were performed using Wilcoxon
Mann-Whitney test. Uncertainty was captured by one-way sensitivity analyses
and probabilistic analysis using a non-parametric bootstrap method. RESULTS: A
total 208 patients were enrolled in seven French centres from January 2007 to May
2011. Protocol deviations reduced the number of patients included in the study to
183. For CBCT, the over cost of daily positioning controls (n67) reached €679 per
patient, compared to weekly controls (n61, p0.0001). For FM, the over cost of
daily positioning controls (n26) reached €187 per patient compared to weekly
controls (n29, p0.0001). Variations in depreciation periods of the accelerator and
time spent by radiotherapists have the highest impact on costs. CONCLUSIONS:
The study highlights incremental costs incurred by different frequencies of posi-
tioning with IGRT in prostate cancers. Cost-effectiveness studies have to be con-
ducted in order to shed further light on which strategy to focus on based on clinical
benefit.
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OBJECTIVES: Companion diagnostics (CD) is a new approach to personalised med-
icines for safer and more efficacious selection of treatments. This review was con-
ducted for cost assessment of CDs in breast cancer (BC). METHODS: Embase® and
MEDLINE®databases were systematically searched until June 2012 to identify eco-
nomic studies on CDs in BC. All economic studies in English language, regardless of
design and diagnostic test assessed were included. Eligibility of studies was as-
sessed by two reviewers with any discrepancy reconciled by a third, independent
reviewer. RESULTS: A total of 202 studies were retrieved; 24 met pre-defined inclu-
sion criteria. Fifteen studies assessed cost of Oncotype Dx, three Mammaprint, two
HercepTest, one IHC, and three both Oncotype Dx and Mammaprint tests. An Irish
study reported that an approximate cost-neutrality (0.4% increase in cost) to its
health care system on adoption of Oncotype DX test (Lacey 2010). Another study in
Canada reported that the introduction of Oncotype DX would result in cost saving
of $27.0m in first year and $28.2m by third year (Hassan 2011).The ICER for Mam-
maPrint was estimated as ¥3,873,922/QALY exhibiting its cost-effectiveness (Kondo
2012). In Israel, Oncotype Dx increased QALY by 0.170 years with $10,770/QALY
gained by reducing the chemotherapy disutility (Klang 2010). In Australia, cost
savings due to reduction in chemotherapy due to Oncotype Dx was estimated to be
$2264/woman. The cost of assay was estimated to be $4200 with a published utility
rate of 0.5, resulting in ICER of $9986/QALY compared without diagnostic test
(O’Leary 2010). CONCLUSIONS: The findings from the published data reflects that
CDs were cost-effective and demonstrated quality of life and survival benefits of a
more targeted approach to treatment decision-making. Literature is suggestive
that using a personalised approach through initial diagnostic tools for BC can help
in reduction of chemotherapy usage and cost savings in health care services.
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OBJECTIVES: Due to the increasing cost pressure, it is necessary to rely on cost-
effective-therapies. Currently there are three monoclonal antibodies (Bevaci-
zumab, Panitumumab, Cetuximab) in the treatment of colorectal cancer, which
differ in their cost structure. Thus, this study aims to compare the costs of ap-
proved therapies from the hospital perspective. METHODS: The cost analysis in-
cludes all direct resources in the course of medication therapy. All relevant direct
medical costs associated with the treatment were detected and quantified: drug
costs of the antibodies, medical consumables, personnel costs and KRAS-testing.
Furthermore, the number-needed-to-treat (NNT) for the three alternatives was
calculated. Additionally, based on the total costs, a cost-effectiveness-depiction
represents the additional costs of the overall-survival (OS) per month. RESULTS:
The absolute benefit of the add-on-therapy leads to a longer progression-free-
survival (PFS) in the treatment-group compared to the control-group. The relative
superiority in PFS for Bevacizumab is 82.4%, 17.9% for Cetuximab and 20% for
Panitumumab. Based on the PFS, the NNT for Bevacizumab accounts for 2 patients,
6 for Cetuximab and 5 for Panitumumab vs. the control-group. According to the
frequency of the number of administrations, the total cost for Bevacizumab
amounts to €2,442.87 per month, €3,693.89 for Cetuximab and €3,671.37 for Panitu-
mumab. The savings of Bevacizumab vs. Cetuximab, based on the total cost, are
€1,251.02 per month. The cost difference of Bevacizumab compared with Panitu-
mumab amounts to €1,228.50 per month. Based on the indirect comparison trial
(ITC), the monthly costs per OS for Bevacizumab amounts to €1,035.19 compared
with Cetuximab (€1,611.55) and Panitumumab (€1,609.19). With regard to the over-
all treatment, the cost savings amounts to €7,581.58 for Bevacizumab compared to
Cetuximab and for Panitumumab €8,719.54. CONCLUSIONS: The presented data of
the cost-comparison-analysis for the approved antibodies therapy are able to dem-
onstrate the possible potential savings through the therapy with Bevacizumab.
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OBJECTIVES: To evaluate the cost-effectiveness of prescribing branded
Taxotere®compared to its generic counterpart docetaxel for patients diagnosed
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